Danish firm Gumlink says it has made further investments in its nutraceutical gum technology, aimed at expanding global applications.
Danish firm Gumlink says it has made further investments in its nutraceutical gum technology, aimed at expanding global applications. The company has invested approximately €10 million, resulting in improved product quality and ability to incorporate a range of active nutritional ingredients.
The company says ingredients can be included at dosage levels comparable to delivery systems such as pills, capsules, and functional beverages. Furthermore, it says, bioavailability studies have documented that “chewing gum as a novel nutritional delivery system is equally efficient as pills/capsules.”
The technology shows great potential for the oral-care market, the company says, which can use the gum to market concepts and ingredients “with a pharmaceutical touch” such as chlorhexidine, oral-care probiotics, antacids, and “a new concept that in terms of efficacy comes quite close to matching the good old toothbrush.”
The company is also proposing the technology for health conditions such as immune defense, weight management, joint health, heart health, and energy. It is currently investigating combining omega-3 with other ingredients in the gum, as well as the use of gum base polymers that stick less to dentures and are more biodegradable.
“As the consumer choices involved with healthcare products are broader and more generic than ever before, we are confident that our unique nutritional delivery system will pave the way for a fast and consumer-friendly adoption, as was the case with nicotine chewing gum in the 1990s,” says Gumlink CEO Soren Birn.